New myostatin drug coming Bimagrumab

Bimagrumab
https://i.ibb.co/VYw4bch9/IMG-9463.jpg https://i.ibb.co/xqHzk6wS/IMG-9464.png
Bimagrumab is a monoclonal antibody that blocks activin II receptors, preventing the activity of myostatin and other negative skeletal muscle regulators that show increased muscle weight and muscle hypertrophy after treatment

In this phase 2 randomized clinical trial, ActRII blockade with bimagrumab led to significant loss of FM, gain in LM, and metabolic improvements during 48 weeks in patients with overweight or obesity who had type 2 diabetes. ActRII pathway inhibition may provide a novel approach for the pharmacologic management of excess adiposity and accompanying metabolic disturbances.

In this study, 48 weeks of exposure to bimagrumab, an antibody inhibitor of ActRII, was safe and effective for treating the excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes. While antibody blockade or knockout of ActRII in animal models is accompanied by marked increases in skeletal muscle mass, this study confirms that inhibition of this receptor in human participants leads to not only increases in lean mass but profound decreases in body fat, along with improvements in glycemic control. Inhibition of ActRII may provide a novel pathway for the pharmacologic management of excess adiposity and accompanying metabolic disturbances.